The impact of the Covid-19 pandemic on people with rare and less common cancers - Report published
Working with Keep up with Cancer[i] Cancer52 has published a new report which covers the impact of Covid-19 on people with rare and less common cancers; and to identify from a wide range of stakeholders any learnings or innovations that could be considered for embedding in the system as services recover and beyond.
Our thanks to our all who gave their time and insight to create this report, and in particular to our member charities who supplied case studies and sat on the working group.
[i] KUWC comprises seven life science companies with a common interest in oncology developments in the UK. They aim to put the UK at the forefront of cancer science and care, working in partnership with the cancer community to improve survival rates and quality of life for people affected by cancer. Its current membership is AstraZeneca (Chair), Gilead Sciences (Vice Chair), Bayer, Bristol Myers Squibb, GlaxoSmithKline, Novartis and Takeda.